
BlueRock Begins Phase III Trial of Cell Therapy Bemdaneprocel with First Parkinson’s Patient Treated
First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced that the first patient has…